REMARKS/ARGUMENTS

After entry of this paper, claims 2-24, 30-35, and 37 are pending. Claim 1 is cancelled, without prejudice, as being drawn to non-elected subject matter. Claims 25-29 and 35-36 are cancelled. Applicants reserve the right to pursue the non-elected subject matter in a divisional application.

Claims 2-24 are amended to depend from claim 30. Claim 30 is amended in independent form by incorporating all of the features of claim 1, now cancelled. Support for this amendment to claim 30 is found throughout the specification and in original claim 1. No new matter is added by these amendments.

Restriction Requirement

The Examiner restricted the claims into two (2) groups and required the election of the subject matter of one group.

As noted above, Applicants elected the subject matter of Group 2, i.e., subject matter drawn to methods of killing cells by photochemotherapy comprising the steps: (i) incubating target cells with an effective amount of a compound defined in Group 1, optionally bound to a carrier which increases the internalization of the compound (ii) allowing sufficient time for the compound to hybridise to a target nucleic acid sequence within the cells; and (iii) irradiating the target cells with electromagnetic radiation of a wavelength that corresponds to at least one absorption wavelength of the photosensitive moiety R such that R interacts through energy transfer with a molecule capable of producing free radicals, to produce free radicals which kill the cells.

Claims 2-24, 30-34 and 37 read on this election.

BHJ7USA

The Director is hereby authorized to charge the extension fee under 37 CFR § 1.17(a)(5) of \$1,115, any deficiency in any fees due with the filing of this paper or during the pendency of this application, or credit any overpayment in any fees to our Deposit Account No. 08-3040.

Respectfully submitted,

Howson & Howson LLP Attorneys for Applicants

By: Mory E. Bok Mary E. Bak

Registration No. 31,215

Suite 210

501 Office Center Drive Fort Washington, PA 19034 Telephone: 215-540-9200

Telefacsimile: 215-540-5818